Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of HD~* Symptoms of dysphagia~* Must be able to swallow tablets~Exclusion Criteria:~* Other confounding diseases that affect swallowing~* Depression~* Hepatic impairment~* Renal impairment~* Dementia

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deutetrabenazine (Type: EXPERIMENTAL): The participants randomized to this group will receive oral deutetrabenazine for 8 weeks. Week 1: 6 mg once daily; Week 2: 6 mg twice daily (BID); Week 3: 9 mg BID; Week 4: 12 BID; Week 5: 15 mg BID; Week 6: 18 mg BID; Week 7: 21 mg BID; Week 8: 24 mg BID.
- Placebo (Type: PLACEBO_COMPARATOR): The participants randomized to this group will receive oral placebo for 8 weeks. Week 1: 6 mg once daily; Week 2: 6 mg twice daily (BID); Week 3: 9 mg BID; Week 4: 12 BID; Week 5: 15 mg BID; Week 6: 18 mg BID; Week 7: 21 mg BID; Week 8: 24 mg BID.

Based on this trial design, predict the completion outcome and termination type (if applicable).